Suchergebnisse - "Tulledge-Scheitel, Sidna M"

PubPharm (55)

1

Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19

enthalten in: bioRxiv.org | 2024

von Ripoll, J. | Tulledge-Scheitel, S. | Stephenson, A. | +21

2

Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19

enthalten in: mBio | 2024

von Ripoll, J. | Tulledge-Scheitel, S. | Stephenson, A. | +21

3

Patient preferences for telehealth services in a large multispecialty practice

enthalten in: Journal of telemedicine and telecare | 2023

von Ebbert, J. | Ramar, P. | Tulledge-Scheitel, S. | +4

4

Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Ranganath, N. | O'Horo, J. | Challener, D. | +5

5

Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19

enthalten in: bioRxiv.org | 2022

von Ganesh, R. | Pawlowski, C. | O’Horo, J. | +17

6

Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch

enthalten in: The Journal of infectious diseases | 2022

von Razonable, R. | O'Horo, J. | Hanson, S. | +9

CommentIn: J Infect Dis. 2022 Nov 11;226(10):1681-1682. - PMID 36124710

7

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch

enthalten in: Open forum infectious diseases | 2022

von Razonable, R. | Tulledge-Scheitel, S. | Hanson, S. | +6

8

Curbing the Delta Surge : Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019

enthalten in: Mayo Clinic proceedings | 2022

von Razonable, R. | O'Horo, J. | Challener, D. | +13

9

Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant

enthalten in: Mayo Clinic proceedings | 2022

von O'Horo, J. | Challener, D. | Speicher, L. | +10

10

Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019

enthalten in: The Journal of infectious diseases | 2021

von Ganesh, R. | Philpot, L. | Bierle, D. | +16

CommentIn: J Infect Dis. 2021 Oct 28;224(8):1275-1277. - PMID 34273151

1
2
3
4
5
6
Nächster »
[6]